Ferring B.v.

Institut Pasteur

Pascal Danglas

Laurent Debarbieux

Sudarkodi Alagarsamy

Michael Reidy

Paul Korner

The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasivestrain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasivestrain thereby treating the subject. The subject invention also provides new bacteriophage strains.

Bacteriophage therapy

This disclosure relates to a method of treating Prader-Willi Syndrome. The method includes administering to a patient in need thereof an effective amount of a composition containing a selective oxytocin receptor agonist or a pharmaceutically acceptable salt thereof.

Growing community of inventors

Saint-Prex, Switzerland

Pascal Danglas